Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para explorar la eficacia de JNJ-89495120 en el tratamiento del trastorno depresivo mayor (Moonlight-1)

24 de septiembre de 2026 actualizado por: Janssen Research & Development, LLC

Un estudio de prueba de concepto aleatorizado, doble ciego, multicéntrico, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de JNJ-89495120 como monoterapia en participantes adultos con trastorno depresivo mayor (TDM)

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

105

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alabama
      • Huntsville, Alabama, Estados Unidos, 35801
        • UAB Huntsville Regional Medical Campus
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
        • Chandler Clinical Trials
      • Phoenix, Arizona, Estados Unidos, 85012
        • IMA Clinical Research PC Phoenix
      • Tucson, Arizona, Estados Unidos, 85724
        • University of Arizona
      • Tucson, Arizona, Estados Unidos, 85704
        • Noble Clinical Research
    • California
      • Bellflower, California, Estados Unidos, 90706
        • CI Trials
      • Encino, California, Estados Unidos, 91316
        • Wake Research PRI Encino
      • Garden Grove, California, Estados Unidos, 92844
        • National Institute Of Clinical Research
      • Newport Beach, California, Estados Unidos, 92660
        • WR-Newport Beach
      • Orange, California, Estados Unidos, 92866
        • ATP Clinical Research
      • Redlands, California, Estados Unidos, 92374
        • Anderson Clinical Research
      • San Diego, California, Estados Unidos, 92103
        • Artemis Institute for Clinical Research
      • San Jose, California, Estados Unidos, 95124
        • Lumos Clinical Research Center LLC
      • Santa Ana, California, Estados Unidos, 92705
        • Syrentis Clinical Research
      • Temecula, California, Estados Unidos, 92591
        • Inland Psychiatric Medical Group Inc
      • Walnut Creek, California, Estados Unidos, 94596
        • Sunwise Clinical Research
    • Colorado
      • Denver, Colorado, Estados Unidos, 80209
        • Mountain View Clinical Research
    • Florida
      • Fort Myers, Florida, Estados Unidos, 33912
        • Gulfcoast Medical Research Center
      • Hollywood, Florida, Estados Unidos, 33021
        • The Medici Medical Research
      • Homestead, Florida, Estados Unidos, 33030
        • Advanced Research Institute of Miami
      • Maitland, Florida, Estados Unidos, 32751
        • K2 Medical Research
      • Miami, Florida, Estados Unidos, 33126
        • Pharmax Research Clinic Inc
      • Miami, Florida, Estados Unidos, 33135
        • Wellness Research Center
      • Pembroke Pines, Florida, Estados Unidos, 33024
        • Best Choice Medical and Research Service
      • Tampa, Florida, Estados Unidos, 33629
        • Interventional Psychiatry of Tampa Bay
      • West Palm Beach, Florida, Estados Unidos, 33407
        • Health Synergy Clinical Research
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30328
        • Synexus Clinical Research US Inc
      • Decatur, Georgia, Estados Unidos, 30030
        • iResearch Atlanta LLC
      • Snellville, Georgia, Estados Unidos, 30078
        • Accelerated Clinical Research Group LLC
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago Medical Center
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University IU Health
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70115
        • DelRicht Research
    • Maryland
      • Gaithersburg, Maryland, Estados Unidos, 20877
        • CBH Health
    • Massachusetts
      • Worcester, Massachusetts, Estados Unidos, 01655
        • University of Massachusetts Medical School
    • New York
      • Brooklyn, New York, Estados Unidos, 11229
        • Integrative Clinical Trials LLC
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • University of Cincinnati
      • Cincinnati, Ohio, Estados Unidos, 45215
        • Patient Priority Clinical Sites LLC
      • Columbus, Ohio, Estados Unidos, 43210
        • OSU Department of Psychiatry and Behavioral Health
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73116
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania
    • South Carolina
      • North Charleston, South Carolina, Estados Unidos, 29405
        • Coastal Carolina Research Center
    • Texas
      • McKinney, Texas, Estados Unidos, 75071
        • Revival Research Institute LLC
    • Utah
      • Clinton, Utah, Estados Unidos, 84015
        • Alpine Research Organization
    • Washington
      • Everett, Washington, Estados Unidos, 98201
        • Core Clinical Research

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 64 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MINI)
  • Participant had to have at least one previous major depressive disorder (MDD) episode prior to their current episode
  • Were first diagnosed with depression before the age of 55
  • Are in a current episode of depression: Episode length must be at least 2 months but not longer than 24 months
  • Have taken 0, 1, or 2 treatments for depression in your current episode
  • Body mass index (BMI) within the range 18 to 35 kilograms per square meter (kg/m^2) at screening

Exclusion Criteria:

  • Treatment with vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), or ketamine/esketamine within the current or past major depressive episodes
  • Current or past DSM-5 diagnosis of bipolar disorder, psychotic disorders, borderline personality disorder, antisocial personality disorder, or current obsessive-compulsive disorder
  • Post-traumatic stress disorder within the past three years of screening
  • Dementia, any dementing disease, intellectual disability, or neurocognitive disorder
  • History of Alcohol and Substance use disorders within 6 months of screening, with the exclusion of nicotine, caffeine, and mild cannabis use disorder, according to the MINI and Clinical Assessment
  • Known allergies, hypersensitivity, or intolerance to JNJ-89495120 or its excipients

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm 1: JNJ-89495120 Dose A

Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study.

JNJ-89495120 will be administered.

Experimental: Arm 2: JNJ-89495120 Dose A and Dose B

Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study.

JNJ-89495120 will be administered.

Comparador de placebos: Arm 3: Placebo Group

Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study.

Placebo will be administered.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 5
Periodo de tiempo: Baseline up to Day 5

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 5

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in MADRS Total Score to Day 2
Periodo de tiempo: Baseline up to Day 2

The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

Baseline up to Day 2
Change from Baseline in Clinician Global Impression-Severity (CGI-S) Scale Score to Days 2 and 5
Periodo de tiempo: Baseline up to Day 2 and Day 5

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Participant is assessed on severity of illness at the time of rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Higher score indicating greater severity.

Baseline up to Day 2 and Day 5
Change from Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score to Day 5
Periodo de tiempo: Baseline up to Day 5

The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item is rated by the participant according to a 5-point Likert scale, where 0 denotes "Not at all" or "Never" and 4 denotes "Extremely" or "Always". Before summing the items to create a total score, item 11 and item 12 are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items, which range from 0 to 60. Higher score indicates more severe depressive symptomatology.

Baseline up to Day 5
Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Scale Score to Day 5
Periodo de tiempo: Baseline up to Day 5

The GAD-7 scale is a self-administered questionnaire designed to measure anxiety. GAD-7 has seven items, which measure frequency of various signs of GAD using a 4-point Likert scale (where, Not at all = 0, Several days = 1, More than half the days = 2, and Nearly every day = 3). The total score ranges from 0 to 21 with increasing scores indicative of greater severity of symptoms of anxiety. Severity of anxiety on the GAD-7 is rated as follows: none (0-4), mild (5-9), moderate (10-14) and severe (15-21).

Baseline up to Day 5
Number of Participants with Adverse Events (AEs)
Periodo de tiempo: Up to approximately 18 weeks

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to approximately 18 weeks
Number of Participants with Abnormalities in Vital Signs Parameters
Periodo de tiempo: Up to approximately 18 weeks

Participants with abnormalities in vital signs (supine blood pressure, pulse/heart rate, respiratory rate, oral temperature) parameters will be reported.

Up to approximately 18 weeks
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Periodo de tiempo: Up to approximately 18 weeks

Participants with 12-lead ECG abnormalities will be reported.

Up to approximately 18 weeks
Number of Participants With Abnormalities in Laboratory Parameters
Periodo de tiempo: Up to approximately 18 weeks

Participants with abnormalities in clinical laboratory parameters (hematology and serum chemistry) will be reported.

Up to approximately 18 weeks
Number of Participants Reporting Changes in Weight/Body Mass Index (BMI)
Periodo de tiempo: Up to approximately 18 weeks

Participants with changes in weight/BMI will be reported.

Up to approximately 18 weeks
Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
Periodo de tiempo: Up to approximately 18 weeks

The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline.

Up to approximately 18 weeks
Change from Baseline in Cognitive Functioning Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R)
Periodo de tiempo: From Baseline up to 4 weeks

The HVLT-R, a measure of verbal learning and memory, is a 12-item word list recall test. Administration includes 3 learning trials, a delayed recall (20-minute) trial, and a 24-word recognition list (including 12 target and 12 foil words). The test administrator reads instructions and word lists aloud, and records words recalled/recognized by the participant. Three learning trials are combined to calculate a total recall score learning, delayed recall, and recognition trials.

From Baseline up to 4 weeks
Change from Baseline in Cognitive Functioning Measured by the Digit Symbol Substitution Test (DSST)
Periodo de tiempo: From Baseline up to 4 weeks

The DSST is recognized as covering all of the cognitive performance aspects: speed of processing, executive functioning, and attention. The DSST measures attention, working memory, sustained visual attention and psychomotor speed. Participants are given a table that pairs digits and symbols, and asked to decipher a code using the table, completing as many as possible in 90 seconds.

From Baseline up to 4 weeks
Plasma Concentrations of JNJ-89495120
Periodo de tiempo: Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Plasma concentrations of JNJ-89495120 will be reported.

Pre-dose (0 hours), and Post-dose on Days 1, 5 and 13

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de diciembre de 2024

Finalización primaria (Actual)

25 de junio de 2026

Finalización del estudio (Actual)

10 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

15 de enero de 2025

Primero enviado que cumplió con los criterios de control de calidad

15 de enero de 2025

Publicado por primera vez (Actual)

20 de enero de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 89495120MDD2001
  • 89495120MDD2001 (Otro identificador: Janssen Research & Development, LLC)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .